Skip to Main content Skip to Navigation
Journal articles

Transarterial Radioembolization (TARE) Agents beyond Y-90-Microspheres

Abstract : Liver malignancies, either primary tumours (mainly hepatocellular carcinoma and cholangiocarcinoma) or secondary hepatic metastases, are a major cause of death, with an increasing incidence. Among them, hepatocellular carcinoma (HCC) presents with a dark prognosis because of underlying liver diseases and an often late diagnosis. A curative surgical treatment can therefore only be proposed in 20 to 30% of the patients. However, new treatment options for intermediate to advanced stages, such as internal radionuclide therapy, seem particularly attractive. Transarterial radioembolization (TARE), which consists in the use of intra-arterial injection of a radiolabelled embolising agent, has led to very promising results. TARE with Y-90-loaded microspheres is now becoming an established procedure to treat liver tumours, with two commercially available products (namely, SIR-Sphere (R) and TheraSphere (R)). However, this technology remains expensive and is thus not available everywhere. The aim of this review is to describe TARE alternative technologies currently developed and investigated in clinical trials, with special emphasis on HCC.
Document type :
Journal articles
Complete list of metadata

Cited literature [172 references]  Display  Hide  Download
Contributor : Laurent Jonchère Connect in order to contact the contributor
Submitted on : Friday, July 12, 2019 - 9:18:01 AM
Last modification on : Tuesday, September 27, 2022 - 4:04:22 AM


Publisher files allowed on an open archive


Distributed under a Creative Commons Attribution 4.0 International License



C. Bouvry, X. Palard, J. Edeline, V. Ardisson, P. Loyer, et al.. Transarterial Radioembolization (TARE) Agents beyond Y-90-Microspheres. BioMed Research International , Hindawi Publishing Corporation, 2018, 2018, pp.1435302. ⟨10.1155/2018/1435302⟩. ⟨hal-02049234⟩



Record views


Files downloads